Protalix Biotherapeutics

Protalix Biotherapeutics company information, Employees & Contact Information

Protalix (NYSE American, TASE: PLX) is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix’s unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix’s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human α Galactosidase A protein for the treatment of Fabry disease; alidornase alfa or PRX 110, for the treatment of various human respiratory diseases or conditions; PRX 115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX 119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.

Company Details

Employees
192
Founded
-
Address
2 Snunit St., Science Park, Pob 455,israel
Phone
972-4-902-8100
Email
bd****@****lix.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
Manager jobs.
HQ
Carmiel
Looking for a particular Protalix Biotherapeutics employee's phone or email?

Protalix Biotherapeutics Questions

News

Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results - PR Newswire

Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results PR Newswire

Protalix BioTherapeutics Earnings: Key Q2 2025 Financial Results and Business Updates Coming August 14 - Stock Titan

Protalix BioTherapeutics Earnings: Key Q2 2025 Financial Results and Business Updates Coming August 14 Stock Titan

Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results - PR Newswire

Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results PR Newswire

Protalix: Speculative Buy On Promising Plant-Cell Platform And Elfabrio Ramp (NYSE:PLX) - Seeking Alpha

Protalix: Speculative Buy On Promising Plant-Cell Platform And Elfabrio Ramp (NYSE:PLX) Seeking Alpha

PEGylated Uricase Well-Tolerated, Demonstrates Dose-Dependent Urate-Lowering - HCPLive

PEGylated Uricase Well-Tolerated, Demonstrates Dose-Dependent Urate-Lowering HCPLive

Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results - PR Newswire

Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results PR Newswire

Protalix BioTherapeutics Inc (PLX) Q1 2025 Earnings Call Highlights: Revenue Surge and ... - Yahoo Finance

Protalix BioTherapeutics Inc (PLX) Q1 2025 Earnings Call Highlights: Revenue Surge and ... Yahoo Finance

Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025 - PR Newswire

Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025 PR Newswire

Protalix CFO Eyal Rubin to resign in six months - Investing.com

Protalix CFO Eyal Rubin to resign in six months Investing.com

Protalix BioTherapeutics (PLX): Evaluating Valuation After EMA Setback on Elfabrio Dosing Regimen - Yahoo Finance

Protalix BioTherapeutics (PLX): Evaluating Valuation After EMA Setback on Elfabrio Dosing Regimen Yahoo Finance

Biotech Innovator Protalix BioTherapeutics to Showcase ProCellEx Platform at Q3 Investor Summit Virtual - Stock Titan

Biotech Innovator Protalix BioTherapeutics to Showcase ProCellEx Platform at Q3 Investor Summit Virtual Stock Titan

Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline - Seeking Alpha

Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline Seeking Alpha

Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes® - PR Newswire

Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes® PR Newswire

Major Milestone: Protalix BioTherapeutics Added to Russell 3000 and 2000 Indexes, Gains Access to $10.6T Market - Stock Titan

Major Milestone: Protalix BioTherapeutics Added to Russell 3000 and 2000 Indexes, Gains Access to $10.6T Market Stock Titan

Protalix BioTherapeutics Issues 2025 Letter to Stockholders - PR Newswire

Protalix BioTherapeutics Issues 2025 Letter to Stockholders PR Newswire

Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer - PR Newswire

Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer PR Newswire

Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - PR Newswire

Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference PR Newswire

Protalix BioTherapeutics Provides Update on Complete Response Letter for Pegunigalsidase Alfa from the FDA - PR Newswire

Protalix BioTherapeutics Provides Update on Complete Response Letter for Pegunigalsidase Alfa from the FDA PR Newswire

Protalix BioTherapeutics Announces 1-for-10 Reverse Stock Split - PR Newswire

Protalix BioTherapeutics Announces 1-for-10 Reverse Stock Split PR Newswire

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease - PR Newswire

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease PR Newswire

Protalix BioTherapeutics lifts revenue on strong Elfabrio demand - Proactive financial news

Protalix BioTherapeutics lifts revenue on strong Elfabrio demand Proactive financial news

Protalix BioTherapeutics Reports Strong Q2 2025 Results - TipRanks

Protalix BioTherapeutics Reports Strong Q2 2025 Results TipRanks

Protalix Amends Market Offering Agreement with H.C. Wainwright - TipRanks

Protalix Amends Market Offering Agreement with H.C. Wainwright TipRanks

Protalix earnings missed by $0.15, revenue topped estimates - Investing.com

Protalix earnings missed by $0.15, revenue topped estimates Investing.com

Protalix BioTherapeutics - The Pharma Letter

Protalix BioTherapeutics The Pharma Letter

Protalix BioTherapeutics Announces Closing of $43.7 Million Private Placement - PR Newswire

Protalix BioTherapeutics Announces Closing of $43.7 Million Private Placement PR Newswire

Large-scale production of pharmaceutical proteins in plant cell culture—the protalix experience - Wiley Online Library

Large-scale production of pharmaceutical proteins in plant cell culture—the protalix experience Wiley Online Library

Plant-Cell Cultures and Cell Lines for Recombinant Protein Expression - BioProcess International

Plant-Cell Cultures and Cell Lines for Recombinant Protein Expression BioProcess International

PLX Stock Price and Chart — AMEX:PLX - TradingView

PLX Stock Price and Chart — AMEX:PLX TradingView

Plant-based oral delivery of β-glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease - Wiley Online Library

Plant-based oral delivery of β-glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease Wiley Online Library

Top Protalix Biotherapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant